Experimental and clinical evidence suggests that the new drugs bedaquiline ( B ) and pretomanid ( Pa ) , combined with an existing drug , pyrazinamide ( Z ) , and a repurposed drug , clofazimine ( C ) , may assist treatment shortening of drug-susceptible and drug-resistant tuberculosis .